CD274 and neoplasm: In the past five years, the main burst keywords related to immunotherapy for cervical cancer included Nivolumab (8.96), cancer immunotherapy (4.61), immune checkpoint inhibitor (13.55), tumor microenvironment (13.7), Pembrolizumab (12.94), PD-L1 expression (6.95), and immune infiltration (4.18).